Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial

Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in brain and periphery. Augmentation with drugs that lower this pro-inflammatory status may improve clinical presentation. Simvastatin crosses the blood-brain barrier, has anti- inflammatory and neuroprot...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Schizophr Bull
Autors principals: Sommer, Iris E, Gangadin, Shiral S, de Witte, Lot D, Koops, Sanne, van Baal, C, Bahn, Sabine, Drexhage, Hemmo, van Haren, N E M, Veling, Wim, Bruggeman, R, Martens, Peter, Wiersma, Sybren, Veerman, Selene R T, Grootens, Koen P, van Beveren, Nico, Kahn, Rene S, Begemann, Marieke J H
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2021
Matèries:
Regular Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8266622/
https://ncbi.nlm.nih.gov/pubmed/33608711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbab010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars